Cell Technologies in the Stress Urinary Incontinence Correction

Abstract

The scientific literature of recent years contains a lot of data about using multipotent stromal cells (MSCs) for urinary incontinence correction. Despite this, the ideal treatment method for urinary incontinence has not yet been created. The cell therapy results in patients and experimental animals with incontinence have shown promising results, but the procedures require further optimization, and more research is needed to focus on the clinical phase. The MSC use appears to be a feasible, safe, and effective method of treatment for patients with urinary incontinence. However, the best mode for application of cell technology is still under study. Most clinical investigations have been performed on only a few patients and during rather short follow-up periods, which, together with an incomplete knowledge of the mechanisms of MSC action, does not make it possible for their widespread implementation. The technical details regarding the MSC application remain to be identified in more rigorous preclinical and clinical trials.

The Systematic Review of Stem Cell Therapy for Stress Urinary Incontinence

“…However, several organizations has frequently issued warnings against the use of mesh materials in the treatment of female urinary incontinence as the result of many severe adverse events. 12,13 Stem cells are classically thought to improve tissue repair via multilineage differentiation and self-renewal. Stem cells may also exert a therapeutic effect via the secretion of bioactive factors that have antiapoptotic,mantiscarring, neovascularization, and immunomodulatory effects on innate tissues and can direct innate stem and progenitor cells to the area of injury.…”

Perinatal mesenchymal stromal cells of the human decidua restore continence in rats with stress urinary incontinence induced by simulated birth trauma and regulate senescence of fibroblasts from women with stress urinary incontinence

“…There are many sources of MSC such as bone marrow, adipose tissue, or perinatal derivatives, among others ( Ledesma-Martinez et al, 2016 ; Torre and Flores, 2020 ; Gao et al, 2021 ; Krawczenko and Klimczak, 2022 ). MSC transplantation has been tested in preclinical SUI models and has been shown to be safe, feasible, and effective in repairing tissue deficiencies ( Sima and Chen, 2020 ; Maiborodin et al, 2022 ). MSC from different tissues have been tested in these preclinical models such as from bone marrow ( Janssen et al, 2019 ), adipose tissue ( Cui et al, 2018 ; Ni et al, 2018 ), dental pulp ( Zordani et al, 2019 ), urine ( Wu et al, 2019 ), and muscle ( Bilhar et al, 2018 ; Cui et al, 2018 ).…”